TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00724932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine
Description: After the last dose of rocuronium has been administered, participants will receive, according to the randomization, 50 μg.kg-1 neostigmine (with atropine in a ratio of 5:1 for neostigmine:atropine) at reappearance of T2.
Study: NCT06715176

Intervention type: OTHER
Intervention: Clinical periodontal measurements at baseline (T0)
Description: Full-mouth clinical periodontal measurements, including PD, CAL, GI, and PI were recorded at 6 sites per tooth, except the third molars, at baseline (T0). A manual periodontal probe was used for PD (millimeters) and CAL (millimeters) measurements; the cemento-enamel junction was used as a reference point for the measurement of CAL.
Study: NCT01714869

Intervention type: OTHER
Group type: OTHER
Intervention: Swedish Massage
Description: Swedish Massage, once per week for 8 weeks, 60 minutes per session.
Study: NCT01029015

Intervention type: PROCEDURE
Intervention: polysomnography
Description: recording device measuring sleep activity through electrodes attached to the subject
Study: NCT01541267

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aliskiren, eplerenon, telmisartan
Description: aliskiren (Rasilez 300 mg, Novartis Europharm eplerenon (Inspra 50 mg, Pfizer Europe) telmisartan (Micardis 80 mg, Boehringer Ingelheim)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aliskiren, eplerenon, telmisartan
Description: aliskiren (Rasilez 300 mg, Novartis Europharm eplerenon (Inspra 50 mg, Pfizer Europe) telmisartan (Micardis 80 mg, Boehringer Ingelheim)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aliskiren, eplerenon, telmisartan
Description: aliskiren (Rasilez 300 mg, Novartis Europharm eplerenon (Inspra 50 mg, Pfizer Europe) telmisartan (Micardis 80 mg, Boehringer Ingelheim)
Study: NCT03991884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study: NCT03991884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study: NCT03991884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO or IV
Study: NCT00724932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: After the last dose of rocuronium has been administered, participants will receive, according to randomization, 10 μg.kg-1 atropine (with neostigmine in a ratio of 5:1 for neostigmine:atropine) at reappearance of T2.
Study: NCT03369093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Twice daily doses of injectable amoxicillin
Study: NCT00338572

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program
Description: Participants in the exercise group will receive a 12-week membership to the YMCA and will meet with a personal trainer twice a week. They will be encouraged to exercise on their own for an additional 3 to 4 days per week. Participants will also be provided with a pedometer, which will track the number of steps they take each day.
Study: NCT03991884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT02776514

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcort
Description: Fluoroscopic guided injection in the knee joint

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-rich-plasma
Study: NCT03991884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT06715176

Intervention type: OTHER
Intervention: Clinical periodontal measurements at baseline (T0)
Description: Full-mouth clinical periodontal measurements, including PD, CAL, GI, and PI were recorded at 6 sites per tooth, except the third molars, at baseline (T0). A manual periodontal probe was used for PD (millimeters) and CAL (millimeters) measurements; the cemento-enamel junction was used as a reference point for the measurement of CAL.

Intervention type: OTHER
Intervention: Saliva collection at baseline (T0)
Description: Unstimulated whole saliva was collected from all participants at baseline (T0). The participants were instructed to refrain from mechanical or chemical oral hygiene practices, eating, drinking, and chewing gum for 2 hours prior to sample collection. Every participant rinsed the mouth with tap water for 2 minutes. Ten minutes after rinsing, they were told to allow the accumulation of the saliva in their mouths and then to drain passively the saliva pool from the lower lip into a steril container for 5 minutes.

Intervention type: OTHER
Intervention: Saliva collection at baseline (T0)
Description: Unstimulated whole saliva was collected from all participants at baseline (T0). The participants were instructed to refrain from mechanical or chemical oral hygiene practices, eating, drinking, and chewing gum for 2 hours prior to sample collection. Every participant rinsed the mouth with tap water for 2 minutes. Ten minutes after rinsing, they were told to allow the accumulation of the saliva in their mouths and then to drain passively the saliva pool from the lower lip into a steril container for 5 minutes.
Study: NCT03991884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Given IV
Study: NCT06715176

Intervention type: OTHER
Intervention: Saliva collection at baseline (T0)
Description: Unstimulated whole saliva was collected from all participants at baseline (T0). The participants were instructed to refrain from mechanical or chemical oral hygiene practices, eating, drinking, and chewing gum for 2 hours prior to sample collection. Every participant rinsed the mouth with tap water for 2 minutes. Ten minutes after rinsing, they were told to allow the accumulation of the saliva in their mouths and then to drain passively the saliva pool from the lower lip into a steril container for 5 minutes.

Intervention type: OTHER
Intervention: Saliva collection at baseline (T0)
Description: Unstimulated whole saliva was collected from all participants at baseline (T0). The participants were instructed to refrain from mechanical or chemical oral hygiene practices, eating, drinking, and chewing gum for 2 hours prior to sample collection. Every participant rinsed the mouth with tap water for 2 minutes. Ten minutes after rinsing, they were told to allow the accumulation of the saliva in their mouths and then to drain passively the saliva pool from the lower lip into a steril container for 5 minutes.
Study: NCT04350229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug omission
Description: Drug omission. In the experimental group, dexamethasone will be omitted from the second application of paclitaxel.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: No drug omission. In the control group, dexamethasone will not be omitted in the second application of paclitaxel.
Study: NCT00760604

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagectomy
Description: Comparison of en-bloc vs. non-en bloc esophagectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagectomy
Description: Comparison of en-bloc vs. non-en bloc esophagectomy
Study: NCT00405821

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyclovir
Description: 400mg twice daily for 24 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet twice daily for 24 months
Study: NCT02907320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYCLO 3 ® FORT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MPFF

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo CYCLO 3 ® FORT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo CYCLO 3 ® FORT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo MPFF

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo MPFF
Study: NCT06715176

Intervention type: OTHER
Intervention: Scaling and root planing
Description: Periodontitis patients (grade B and C) underwent a program of non-surgical periodontal therapy consisting of conventional quadrant-based scaling and root planing using ultrasonic instruments and manual periodontal curette over four visits at 1-week intervals. All present teeth were instrumented until the root surface was visually and tactilely clean and smooth. Patients who did not respond to treatment at baseline (T0) received a further round of scaling and root planing at three (T3) months post-therapy in order to eliminate residual pockets.

Intervention type: OTHER
Intervention: Scaling and root planing
Description: Periodontitis patients (grade B and C) underwent a program of non-surgical periodontal therapy consisting of conventional quadrant-based scaling and root planing using ultrasonic instruments and manual periodontal curette over four visits at 1-week intervals. All present teeth were instrumented until the root surface was visually and tactilely clean and smooth. Patients who did not respond to treatment at baseline (T0) received a further round of scaling and root planing at three (T3) months post-therapy in order to eliminate residual pockets.

Intervention type: OTHER
Intervention: Clinical periodontal measurements at T1, T3, and T6.
Description: Full-mouth clinical periodontal measurements were performed for all periodontitis patients (grade B and C) at one (T1), three (T3) and six (T6) months after scaling and root planing.

Intervention type: OTHER
Intervention: Clinical periodontal measurements at T1, T3, and T6.
Description: Full-mouth clinical periodontal measurements were performed for all periodontitis patients (grade B and C) at one (T1), three (T3) and six (T6) months after scaling and root planing.

Intervention type: OTHER
Intervention: Saliva collection at T1, T3, and T6.
Description: Unstimulated whole saliva were collected from all periodontitis patients (grade B and C) at one (T1), three (T3) and six (T6) months after scaling and root planing.

Intervention type: OTHER
Intervention: Saliva collection at T1, T3, and T6.
Description: Unstimulated whole saliva were collected from all periodontitis patients (grade B and C) at one (T1), three (T3) and six (T6) months after scaling and root planing.
Study: NCT03585192

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin Group
Description: 1. If the newborn is vigorous (crying, good respiratory effort, good tone) after vaginal delivery, newborn will be able to go directly to Mother's chest for immediate SSC~2. A pulse oximeter will be placed on the newborn's right wrist. Saturations will be monitored on a pulse oximeter located next to the Mother's bed for the first hour of life.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Warmer Group
Description: 1. Newborn will go to the radiant warmer, pulse oximeter placed on newborn's right wrist, and saturations will be monitored on the Panda Warmer.~2. If stable per Baby RN after 20 minutes of observation, the newborn will be placed on Mother's chest for SSC. Vital signs will be monitored for the first hour of life.
Study: NCT00338572

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Exercise and Diet Program
Description: Participants in this group will receive a 12-week membership to the YMCA and will meet with a personal trainer twice a week. They will be encouraged to exercise on their own for an additional 3 to 4 days per week. Participants will also be provided with a pedometer, which will track the number of steps they take each day. They will meet with a dietician and will be encouraged to reduce their caloric intake by incorporating low-fat, high-fiber foods into their diet.
Study: NCT00640549

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: After a run-in phase of 4 weeks eligible patients were randomized at a ratio of 2 : 1 (atorvastatin : placebo). Patients in the atorvastatin group were treated with atorvastatin 20 mg tablets administered once daily orally for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After a run-in phase of 4 weeks eligible patients were randomized at a ratio of 2 : 1 (atorvastatin : placebo). Patients in the placebo group were treated with placebo 20 mg tablets administered once daily orally for 8 weeks.
Study: NCT00580918

Intervention type: OTHER
Intervention: functional magnetic resonance imaging fMRI
Description: functional magnetic resonance imaging fMRI

Intervention type: OTHER
Intervention: functional magnetic resonance imaging fMRI
Description: functional magnetic resonance imaging fMRI
Study: NCT02051491

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BP-NCPAP
Description: Initial settings of BP-NCPAP will be a lower level PEEP of 5 cm H2O and a higher level PEEP of 8 cm H2O at a cycle rate of 20 per minute with 1 second at the higher PEEP per cycle. The settings can then be adjusted and titrated up to a maximum of 7 and 10 cm H2O for the lower and higher PEEPs respectively at a maximum rate of 30 cycles per second based on FiO2 requirements.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIHFV
Description: The initial settings will be a MAP of 8 cm H2O, frequency of 10 Hz, and amplitude of 20 cm H2O. The maximum allowable MAP will be 10 cm of H2O. The range of frequency allowed will be 6 - 14 Hz. Both frequency and amplitude will be adjusted to try and achieve palpable/visible chest movement and to achieve target CO2 levels for the particular patient.
Study: NCT04103723

Intervention type: PROCEDURE
Intervention: Preoperative premedication
Description: Every patient with or without a preoperative premedication with midazolam before surgery.

Intervention type: PROCEDURE
Intervention: Preoperative premedication
Description: Every patient with or without a preoperative premedication with midazolam before surgery.
Study: NCT00490100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Increlex
Study: NCT02776514

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suplasyn1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04788160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical SNAGs along with conventional therapy
Description: cervical SNAG half rotation technique will be performed with the patient sitting on a chair in the erect posture. The therapist placed his thumb over thumb over the transverse process of C1. Then, he glided ventrally with active rotation of the restricted site 10 times holding for 10 seconds with overpressure at end of the rotation with 30 second rest in between each repetition and 3 session/week for 4 weeks.~* Conventional therapy will include:~* Hot pack over the cervical region for 10 minutes.~* TENS for 10 minutes.~* Furthermore, general stretching the upper cervical muscles will be done with 5 repetitions with 3 sessions/week for 4 weeks.~* Isometric cervical extensor exercise with 10 seconds hold for 10 times will be done.~* Cervical flexor strengthening will be done 10 times in sitting position.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Therapy
Description: * Patients in this group will undergo only conventional therapy which will include:~* Hot pack for 15 minutes.~* TENS for 10 minutes.~* Furthermore, general stretching the upper cervical muscles will be done with 5 repetitions each 3 sessions/week for 4 weeks.~* Isometric cervical extensor exercise with 10 seconds hold for 10 times will be done.~* Cervical flexor strengthening will be given to the patient by the therapist, 10 times in sitting position.
Study: NCT01568866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib is administered over 30 minutes as an infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib is administered as a 3-5 second bolus IV injection or SC injection (in accordance with regulatory approval)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Tablet for oral administration; On days when carfilzomib or bortezomib was administered, the dexamethasone was to be given 30 minutes to 4 hours prior to the carfilzomib or bortezomib dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablet for oral administration; On days when carfilzomib or bortezomib was administered, the dexamethasone was to be given 30 minutes to 4 hours prior to the carfilzomib or bortezomib dose.
Study: NCT03698266

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Needle knife fistulotomy
Description: A needle knife fistulotomy uses a tiny knife to cut directly into the ampulla to gain access to the biliary system in patients undergoing ERCP
Study: NCT01516866

Intervention type: PROCEDURE
Intervention: Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) imaging
Description: Subjects who will be enrolled will be those who will be starting treatment (as part of standard of care or as part of another trial) with either a microtubule directed chemotherapy regimen (cohort A), or AR-directed therapy (cohort B). All subjects will have a baseline NaF PET/CT scan (baseline #1), performed within days prior to starting either chemotherapy or AR-directed therapy. A subset of subjects (up to 20 subjects per site, 60 total) will undergo a second NaF PET/CT scan (baseline #2) within 1-8 days of the initial scan to determine repeatability of NaF PET/CT scanning. Subjects in cohort A will undergo another NaF PET/CT scan at week 8 (+/- 1 week). Subjects in cohort B will undergo two additional NaF PET/CT scans at weeks 6 and 12 (+/- 1 week).

Intervention type: PROCEDURE
Intervention: Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) imaging
Description: Subjects who will be enrolled will be those who will be starting treatment (as part of standard of care or as part of another trial) with either a microtubule directed chemotherapy regimen (cohort A), or AR-directed therapy (cohort B). All subjects will have a baseline NaF PET/CT scan (baseline #1), performed within days prior to starting either chemotherapy or AR-directed therapy. A subset of subjects (up to 20 subjects per site, 60 total) will undergo a second NaF PET/CT scan (baseline #2) within 1-8 days of the initial scan to determine repeatability of NaF PET/CT scanning. Subjects in cohort A will undergo another NaF PET/CT scan at week 8 (+/- 1 week). Subjects in cohort B will undergo two additional NaF PET/CT scans at weeks 6 and 12 (+/- 1 week).
Study: NCT03493776

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VZV subunit vaccine
Description: VZV subunit vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VZV subunit vaccine
Description: VZV subunit vaccine
Study: NCT02006368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Collection and autologous re-infusion
Description: Subjects will donate one unit of whole blood. This unit will be stored at 4°C for a predefined storage period. A variety of in vitro metabolic and functional platelet assays will be performed on the stored unit.~After the storage period, an aliquot from the whole blood unit will be processed to obtain platelets. The subject will return and donate a fresh sample of whole blood (43 mls) from which a fresh aliquot of platelets will be obtained. The stored and fresh platelets will each be labeled with a different radioisotope (either Chromium-51 or Indium-111) and reinfused into the subject. Using two different radioisotopes enables separate tracking of both the stored and fresh platelets. Follow-up blood samples will be drawn at 2 hours and on days 1, 2, 3, 5, 7±1 and 10±2. Stored and Fresh platelet recoveries and survivals will be calculated.
Study: NCT05250674

Intervention type: DEVICE
Intervention: CEM-guided biopsy
Description: The evaluation population consists of adult women, presenting with clinical indication for a breast biopsy procedure after a positive abnormal CEM or MRI examination (with no clear ultrasound or mammography correlation) and considered eligible for this procedure as per standard of care.~Eligible subjects undergo the clinically indicated breast biopsy procedure using the Pristina Serena Bright ® CEM-guided biopsy. Region of interest location is determined by using stereotactic pairs of CEM images after injection of iodinated contrast media. All necessary equipment and instrumentation, medications, or other devices required to complete the subject's clinically indicated procedure shall be used and are not expected to be influenced by evaluation participation.
Study: NCT06716567

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: Alpharix-Tetra®, Vaxigrip Tetra® and Influvac Tetra® were used as influenza vaccines in the 2020-2021, 2021-2022, and 2022-2023 seasons respectively.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: Alpharix-Tetra®, Vaxigrip Tetra® and Influvac Tetra® were used as influenza vaccines in the 2020-2021, 2021-2022, and 2022-2023 seasons respectively.
Study: NCT02640144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hyaluronate 1%
Description: Intra articular knee injection following arthroscopy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intra articular knee injection following knee arthroscopy. Serves as a placebo. This is the actual buffer of the ARTHREASE injection.